risedronic acid has been researched along with Parkinson Disease in 4 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Urinary deoxypyridinoline, a bone resorption marker, decreased by 46." | 2.73 | Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007) |
| "After patients with osteoporosis are identified, the challenge is to treat them appropriately." | 2.47 | Treatments for osteoporosis in people with a disability. ( Smith, EM, 2011) |
| "Neurological diseases, including Alzheimer's disease, stroke, and Parkinson's disease have been reported to increase the risk for fractures." | 2.44 | Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials. ( Iwamoto, J; Matsumoto, H; Takeda, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smith, EM | 1 |
| Sato, Y | 2 |
| Iwamoto, J | 3 |
| Honda, Y | 2 |
| Matsumoto, H | 1 |
| Takeda, T | 1 |
2 reviews available for risedronic acid and Parkinson Disease
| Article | Year |
|---|---|
Treatments for osteoporosis in people with a disability.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Etidronic Acid; Hu | 2011 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Conf | 2008 |
2 trials available for risedronic acid and Parkinson Disease
| Article | Year |
|---|---|
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administratio | 2011 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo | 2007 |